| Biotech Co (Country/ Symbol) | Agbiotech Partner (Country/ Symbol) | Type/ Product Area | Disclosed Funding (M) | Terms/Details (Month) |
| Affymax Technologies NV (unit of Glaxo Wellcome plc; UK; NYSE:GLX) | DuPont Crop Protection (unit of DuPont; NYSE:DD) | Research and development collaboration/access to Affymax chemical libraries for testing against crop protection targets | ND | Affymax will receive fees for compound access and testing, plus milestones and royalties on any products that emerge (2/00) |
| AgriBioTech Inc. | Kenneth R. Budd (former COO and president of AgriBioTech) and J.R. Simplot Co. | Sale of assets/turfgrass seed assets and specialty division | $65 | Sale is subject to various closing condition (5/00) |
| AgrBioTech Inc. | Research Seeds Inc. | Sale of assets/all assets of AgriBioTech's forage business unit | $16 | Research Seeds agreed to pay $16M in cash, subject to various pre-closing conditions (6/00) |
| Agrinomics LLC (unit of Agritope Inc.; AGTO) and Aventis Crop Science (unit of Aventis SA; France; NYSE:AVE) | Vilmorin Clause & Cie (France) and Biotech M.A.H. Plant Genomic Fund (Israel) | Research collaboration/discovery of genes that confer desirable traits in vegetables | $7.50 | A Vilmorin/Biotech M.A.H. joint venture will sponsor the $7.5M research program;Agrinomics received $1.5M up front to fund the first year of research (2/00) |
| Agritope Inc. (AGTO) | Rohm and Haas Co. (NYSE:ROH) | Technology development and marketing agreement/create a new plant transformation marker selection system for use in agricultural biotechnology | ND | Once developed, the system will permit the rapid creation of improved plant varieties; both companies will conduct research and any royalties will be shared equally; Rohm and Haas will manufacture the ligand and market the transformation marker system (9/00) |
| Akkadix Corp. | Pangene Corp. | License/Pangene s Homologous Recombination and other related technologies | ND | Akkadix receives license to technologies for commercial use in the plant science field; Pangene also has been granted a nonexclusive cross-license to Akkadix s bioinformatics technology (9/00) |
| Akkadix Corp. | Samuel Roberts Noble Foundation | Research/improving the quality and digestibility of forage crops | ND | Initial target for the project is alfalfa; Akkadix will provide research support and its bioinformatics to identify genes in return for access to resulting developments (11/00) |
| Aleurone Corp. | Monsanto Co. (unit of Pharmacia Corp.; NYSE:PHA) | License/Aleurone's genetic engineering technology for cereal plants expressing foreign proteins in seed storage areas | ND | Aleuron will receive up-front payment and royalties on sales (1/00) |
| AMBI Inc. (AMBI) | ImmuCell Corp. (ICCC) | License/rights to AMBI s Wipe Out product, con sisting of pre-moistened towelettes impregnated with nisin to clean, santize and dry the teat area of a cow prior to milking | $0.36 | ImmuCell paid $0.36M to acquire equipment, trademarks and a license; ImmuCell also agreed to manufacture and supply nisin to AMBI as needed (1/00) |
| AMBI Inc. (AMBI) | ImmuCell Corp. (ICCC) | License/rights to develop and market new antibacterial drugs for animals using nisin and lysostaphin technologies | ND | AMBI received an up-front payment and will receive milestones and royalties on any sales (4/00) |
| Atrix Laboratories Inc. (ATRX) | Pharmacia Corp. (NYSE:PHA) | Marketing/periodontal therapy for companion animals | ND | Pharmacia's animal health unit will market periodontal gel containing doxycycline for use in companion animals; Heska Corp. was formerly marketing partner for the product; Atrix will continue manufacturing the gel (4/00) |
| Aurora Biosciences Corp. (ABSC) | Ceres Inc. | License/Aurora s fluorescent protein technology for use in agricultural applications | ND | Ceres was granted nonexclusive rights to use the technology for in vitro and in vivo research and development activities and to provide services to third parties; the multiyear agreement includes an upfront technology access fee, annual license fees and royalties; Aurora also has an option to acquire equity in Ceres (10/00) |
| AviGenics Inc. | Demegen Inc. (OTC BB:DBOT) | Research and development collaboration/development of chickens resistant to coccidiosis and other avian enteric diseases such as Salmonella and Campylobacter infections | ND | ND (1/00) |
| BioFocus plc (UK) | Aventis CropScience (unit of Aventis SA; France; NYSE:AVE) | Research collaboration/BioFocus will design and supply compounds for agricultural applications | ND | BioFocus gains access to new royalties; further details ND (3/00) |
| Bioject Medical Technologies Inc. (BJCT) | Animal Medical Center of New York | Provider agreement/use of Bioject's needlefree injectable DNAbased melanoma vaccine in animals | ND | Animal Medical will be the exclusive provider of the product for use in animals (4/00) |
| Celera AgGen (unit of Celera Genomics; NYSE:CRA) | ViaLactia Biosciences New Zealand Ltd. | Research collaboration/Celera will seek to dis cover new bovine genes important for increasing dairy productivity | ND | All intellectual property will be jointly owned (4/00) |
| Ceres Inc. | The Institute for Genomic Research | Collaboration/identify the structure of genes and their encoded proteins in the chromosomes of a plant species | ND | Parties will focus on the plant species Arabidopsis thaliana (12/00) |
| CRS Robotics Corp. (Canada; TSE:ROB) | Monsanto Co. (unit of Pharmacia Corp.; NYSE:PHA) | Supply agreement/CRS will design and provide automated lab systems for high-throughput genotyping | $1.20 | Immediate order, with a value of $1.2M, covers first two systems (5/00) |
| Devgen NV (Belgium) | FMC Corp. (NYSE:FMC) | Expansion of research collaboration/Devgen is discovering targets of existing insecticides and will use the information to make insecticides more target-specific; a second part of the program involves putting candidate targets into C. elegans and using them to screen for novel insecticides | $15 | Expansion of 11/99 deal following fasterthan-expected progress; Devgen will receive $15M in committed research and development fees over three years, plus milestones and royalties (4/00) |
| Diversa Corp. (DVSA) | Aventis Animal Nutrition SA (unit of Aventis SA; France; NYSE:AVE) | Extension of research collaboration/development of a biocatalytic process to manufacture an Aventis product for animal nutrition | ND | Based on progress to date, companies extended initial six-month agreement, resulting in additional research funding to Diversa (4/00) |
| Dow AgroSciences LLC (unit of Dow Chemical Co.; NYSE:DOW) | Boyce Thompson Institute for Plant Research | Multiyear research and collaboration agreement/evaluate and develop plantderived veterinary biologics | ND | Dow and the Boyce Thompson Institute signed the agreement under which scientists will work to accelerate the development and commercialization of plantderived vaccines for the animal health industry (11/00) |
| Enchira Biotechnology Corp. (formerly Energy Biosystems; ENBC) | Genencor International Inc. | License/Enchira's geneshuffling technology for development of genebased products for various industries, including grain processing, animal feed and food ingredients | ND | Licensing agreement is the first of what is expected to be several deals between the companies (5/00) |
| Encore Technologies | Prophyta (Germany) | Exclusive distribution and marketing agreement/Contans WG | ND | Encore will distribute and market Contans WG, a biological fungicide, developed by Prophyta, which controls Sclerotinia diseases in the soil (11/00) |
| EnviroLogix Inc. | Aventis CropScience (unit of Avents SA; France; NYSE:AVE) | License/tests for genetically modified organisms | ND | EnviroLogix will have access to Aventis' BAR and PAT herbicide-resistance proteins and to Cry9C (a Bt protein); further details ND (3/00) |
| EraGen Biosciences | Novartis Agricultural Discovery Institute Inc. (NYSE:NVS) | Collaboration/highthroughput genotyping | ND | EraGen and Novartis will collaborate with Novartis to provide AEGIS (an expanded genetic information system) technology for genotyping; the goal is to accelerate the research and development of methods to protect and improve crops (11/00) |
| Exelixis Pharmaceuticals Inc. (EXEL) | Bayer AG (Germany) | Joint venture/discovery of insecticides and nematicides based on targets discovered by Exelixis using model system genomics | $100 | Companies formed GenOptera LLC under terms of expansion of 6/99 agreement; Exelixis will receive up-front and license payments of $20M, plus milestones and potential royalties; expanded agreement calls for at least $80M in additional research support; Bayer has exclusive marketing rights (1/00) |
| Exelixis Inc. (EXEL) | Dow AgroSciences LLC (unit of Dow Chemical Co.; NYSE:DOW) | Collaboration/develop fungicides and herbicides for crop protection | ND | In a three-year deal, Exelixis will identify and validate targets and format screening assays that will be used by Dow; Dow will provide research funding, as well as milestone payments and royalties (7/00) |
| GeneData AG (Switzerland) | Zeneca Agrochemicals (unit of AstraZeneca plc; UK; NYSE:AZN; and Cytopia Pty Ltd.; Australia) | License/gene expression software | ND | Zeneca will use GeneData s GD Expressionist software for analysis of gene expression array data, supporting development of crop protection products, controlling principal weeds, pests and major crop diseases (8/00) |
| Geron Corp. (GERN) | AviGenics Inc. and Origen Therapeutics Inc. | License/nuclear transfer technology | ND | AviGenics and Origen Therapeutics obtained option rights to license on a nonexclusive, worldwide basis Geron s nuclear transfer technology to generate cloned poultry; Geron will receive equity in each company; terms for the licenses include additional equity and a share in future revenues generated from products under the licenses (12/00) |
| Lion Bioscience AG (Germany) | Paradigm Genetics Inc. (PDGM) | Bioinformatics/development of informatics tools for metabolic profiling that predict the changes of biochemical pathways in plants and fungi; companies will develop phenotypic analysis tools | ND | Project will broaden Lion's i-biology platform to the field of agriculture and will benefit Paradigm's AgDB system (1/00) |
| Lynx Therapeutics Inc. (LYNX) | Aventis CropScience (unit of Aventis SA; France; NYSE:AVE) | Renewal of technology access agreement/use Lynx's genomics discovery services to develop new crop varieties and other agricultural products, and for genomic mapping of certain plants and discovery of of trait-associated single nucleotide polymorphisms | ND | One-year renewal of 3/99 agreement providing nonexclusive access (3/00) |
| Methexis Genomics NV (Belgium) | Sequenom Inc. (SQNM) | Research and development collaboration/use of combined technolo gies to discover and assess genetic variations in targeted regions of human and plant genomes | ND | Companies are collaborating to create and sell products using their combined technologies and may integrate Methexis' technology for discovering single nucleotide polymorphisms with agricultural applications into Sequenom's MassARRAY system (3/00) |
| Neogen Corp. (NEOG) | Agdia Inc. | Development collaboration/determine if grains, oilseeds and vegetables are genetically modified | ND | Companies established a joint venture to develop testing products (6/00) |
| Neurogen Corp. (NRGN) | Pfizer Inc. (NYSE:PFE) | License/development of Neurogen's drug candidates to treat obesity in companion animals, developing pills to block neuropeptide Y neurotransmitters (NPY 1 and NPY 5) | ND | New deal is the sixth between the companies in eight years; it expands the scope of 1995 agreement for NPY antagonists to treat obesity in humans; Neurogen will receive milestones and royalties (6/00) |
| Novalon Pharmaceutical Corp. (unit of Actelion; Switzerland) | Novartis Research Foundation (unit of Novartis AG; Switzerland; NYSE:NVS) | Research collaboration/use of Novalon's BioKey assays for genomic targets in the agricultural field | ND | Novalon will provide BioKey assays for Novartis targets in return for upfront and research and development funding; technology access is nonexclusive (1/00) |
| Oxford Molecular Group plc (UK; LSE:OMG) | Zeneca Agrochemicals (unit of AstraZeneca plc; UK; NYSE:AZN; and Cytopia Pty Ltd.; Australia) | Software agreement | ND | Zeneca purchased Oxford s RS3 Discovery and Diamond Discovery software; companies will work together to develop an advanced combinatorial chemistry software system (8/00) |
| Paradigm Genetics Inc. (PDGM) | Monsanto Co. (unit of Pharmacia Corp.; NYSE:PHA) | Research collaboration/Paradigm will develop functional genomics data by analyzing the product of Monsanto's gene sequencing, bioinfomatics and functional genomics research, creating a product discovery platform for commercialization | $55 | Paradigm will receive $55M in committed payments; additional financial terms ND (1/00) |
| Paradigm Genetics Inc. (PDGM) | Renessen LLC (joint venture of Monsanto Co.; unit of Pharmacia Corp.; NYSE:PHA; and Cargill Inc.) | Expansion of research collaboration/application of functional genomics and bioinformatics to the task of increasing yields of valuable grain components | ND | Paradigm and Monsanto expanded 11/99 agreement to include Renessen (5/00) |
| Protherics plc (UK; LSE:PTI) | Zeneca Agrochemicals (unit of AstraZeneca plc; UK; NYSE:AZN; and Cytopia Pty Ltd.; Australia) | Agreement for Protherics Dock Crunch virtual screening service | US$0.25 | Protherics will provide its services to both companies; the contracts are worth US$250,000 (11/00**) |
| Proteome Systems Ltd. (Australia) | Dow AgroSciences LLC (unit of Dow Chemical Co.; NYSE:DOW) | Research collaboration/use of Proteome's technology to characterize Dow proteins, map diversity of protein families and develop tools to elucidate novel biosynthetic pathways in plants; Proteome will also build several new proteomic databases for the program | ND | Extension and expansion of multiyear agreement initiated 2/99 following achievement of several milestones in the first year of the collaboration (3/00) |
| Rosetta Inpharmatics Inc. (RSTA) | Monsanto Co. (unit of Pfizer Inc.; NYSE:PHA) | Converted pilot agreement to a fullscale, three-year collaboration/development of better crops | $15 | Monsanto will pay Rosetta $15M over three years for the delivery of gene expression information; Rosetta has the potential to receive future payments, including royalties (11/00) |
| SemBioSys Genetics (Canada) | Novartis Agricultural Discovery Institute (unit of Novartis AG; Switzerland; NYSE:NVS) | Development collaboration/development of a product addressing nutraceutical, cosmeceutical and pharmaceutical markets using SemBioSys' oleosin technology (based on genetically engineering oilseeds to produce value-added proteins) | ND | Novartis will fund development; SemBioSys will supply the product to Novartis, which will have exclusive rights (1/00) |
| Strategic Diagnostics Inc. (SDIX) | Novartis Seeds (unit of Novarts AG; Switzerland; NYSE:NVS) | Research and development/genetic tests for quality control in foun dation seeds and crop breeding | ND | Strategic Diagnostics will distribute the tests (6/00) |
| Symyx Technologies Inc. (SMMX) | Celanese AG (Germany; NYSE:CZ) | Extension of research collaboration/discovery of new catalysts to convert basic feed stocks into higher value-added commodity chemicals | $5 | Celanese will have exclusive rights to use catalysts discovered by Symyx in the defined field; Symyx will receive over $5M in research funding during the one-year extension (through 2/02) plus royalties on the sale of chemicals produced by the catalysts (5/00) |
| Trega Biosciences Inc. (TRGA) | DuPont Crop Protection (unit of DuPont; NYSE:DD) | Compound library access/Trega will supply small-molecule chemistry libraries through its Chem.Folio program | ND | Trega will receive an up-front payment and potential milestones and royalties; agreement includes possibility of further collaboration in the future (1/00) |
| Univera Pharmaceuticals Inc. | Unigen Ltd. (Korea) | License and research collaboration/transfer of Univera's PhytoLogix and PhytoGenEx technologies to Unigen and the sharing of future technical improvements | $1 | Univera received a $1M license fee and will receive royalties on future improvements; as part of the agreement, the companies will collaborate on plant screening (5/00) |
| Notes: This chart contains information on new corporate agreements in agricultural biotechnology covering the time between 1/1/00 and 12/31/00; stocks trade on Nasdaq unless otherwise noted. AMEX = American Stock Exchange; LSE = London Stock Exchange; NYSE = New York Stock Exchange; OTC BB = Over The Counter Bulletin Board; ND = Not disclosed, reported and/or available ** Denotes the date the item ran in BioWorld International. | ||||